Please be aware that Mahajan Imaging & Labs will never request for your bank details or OTP for booking/registration purposes.

What is a LUNG CANCER PANEL- 12 GENE WITH PDL1-DAKO 22C3?

Lung Cancer Panel - 12 Gene with PD-L1 (Dako 22C3) is a specialized molecular diagnostic test designed for patients with advanced non-small cell lung cancer (NSCLC). It simultaneously analyzes 12 key lung cancer driver genes for clinically actionable mutations and fusions, along with PD-L1 protein expression using the FDA-approved Dako 22C3 immunohistochemistry assay. This comprehensive panel helps oncologists select the most effective targeted therapies or immunotherapy, predict treatment response, and guide personalized treatment decisions for better clinical outcomes in lung cancer patients.

Additional Information

Also known as/ Other names: Comprehensive Lung Cancer Molecular Panel, NSCLC 12-Gene Panel with PD-L1, Lung Tumor Mutation Panel with PD-L1 22C3, Lung Cancer Biomarker Panel
Parameters: 1
Recommended for: M/F/Others
Sample Type: FFPE Tissue block
Patient Preparation: Sample should pass the DNA QC process. In case QC fails patients will be informed within 8-10 days.
Reports: 15 days

FAQs

Can this test detect all lung cancer mutations?

It covers the most common actionable genes in lung cancer. For broader analysis, a larger genomic panel may be needed.

Who should undergo this Lung Cancer Panel?

It is recommended for patients with advanced or metastatic non-small cell lung cancer (NSCLC) to guide personalized treatment.

Why is this test recommended?

It helps identify actionable mutations and PD-L1 status to guide targeted therapy and immunotherapy decisions in non-small cell lung cancer.

Does this panel detect gene fusions?

Certainly, it typically detects important fusions such as ALK, ROS1, RET, and NTRK fusions.

How is PD-L1 reported?

PD-L1 is reported as Tumor Proportion Score (TPS) percentage using the Dako 22C3 antibody.

Can this test be done on blood (liquid biopsy)?

No, this panel requires tumor tissue. Liquid biopsy options test fewer genes and are not standard for PD-L1.

Recommend more for you

Book Your Test
Text copied to clipboard
Dynamic badges will be added here